EGFR and cancer: In this study, we showed that HDACinhibitors (HDACi) were able to disrupt the EGF-signaling in colon cancer cells.EGFR expression in these cells as well as other origins such as epidermoid (A431)and breast (MDA-MB468) was decreased by HDACi, suggesting the potential of HDACi totreat EGFR overexpressing cancers.